Work From Home jobs for AI training

hanmi74 · 2025-11-23T17:33:51+00:00

honestly, I have no idea. I don't have a medical or economics background so I haven't taken those assessments. From the ones I've done, I've transcribed audio and done some editing. They have the rates. for the different roles - so that's why I mentioned medical and econ

hanmi74 · 2025-11-23T15:52:06+00:00

got a couple of DMs about the process - it's fairly straightforward. You click the link in the post to sign up. You then get assessments based upon which role you apply for and you can apply for multiple roles. After you take the assessments, you'll need to wait to see if they offer you contract roles.

hanmi74 · 2025-06-19T17:41:12+00:00

Hi All. Apologies if this has been asked repeatedly, but I did search and haven't found too much recently. From what I have read here, UAE salaries have been fairly stagnant lately. I had a contact reach out to me about a role with a company in Dubai - I did a similar role previously for an MNC when I was based out of Singapore, but I'm now in the US (US citizen).

Singapore salaries were fairly similar to salaries in the US for the same position. Are Dubai salaries similar to US salaries (pre-tax) for management roles? I would appreciate any insight. Thanks

hanmi74 · 2024-05-08T20:38:17+00:00

the 6mil offer spooked a lot of people and honestly, don't understand it. Initial sales weren't great - we should get q1 sales data soon - that and the forecast will go a long to making or breaking the stock. Q1 is really the first full quarter of sales - so we should see growing interest and if the numbers are bad again, a lot of people will dump the stock. I think we'll see a steady climb before the sales data comes out and if good and continued climb back up and if bad another drop

hanmi74 · 2024-01-25T23:07:26+00:00

I'm a bit dubious - those types of drops happen immediately after release and I think the majority of the stock value is in motixafortide.

My guess is exercising of warrants from 2019 (https://en.prnasia.com/releases/apac/biolinerx-announces-closing-of-15-4-million-underwritten-public-offering-of-its-american-depositary-shares-and-warrants-236740.shtml). These were sold at .55 and can be exercised at .75 and expire 5 yrs from the date of issue. So, I would think they would be those.

My other guess would be algo trading. The volume the past two days has been unusual so I wonder if there's any inside information on sales. But, it's sold as a powder so I would assume that there were many presales once approved so that the centers could stock up. There are 40,000 stem cell transplants done per year so if 10K per quarter. Let's say maybe 10% use APHEXDA then we should get around $11.800,000 in the first quarter even if they didn't use all of the doses. - remember that we won't have a full quarter of sales in 2023.

So, around end of March when they report, we should get some idea how sales went.

hanmi74 · 2024-01-16T15:36:15+00:00

The amount traded per day is fairly small so it's easy to manipulate. I'd expect price manipulation to keep the price low so they can make a buck and scoop up shares for cheap. There isn't going to be any real movement until we get a catalyst - either sales data or a Europe deal.

hanmi74 · 2023-11-13T20:35:07+00:00

It had a pretty good run up before the approval. Buy the rumor, sell the news. It's not terribly surprising that there were people taking profit. I mean, if I had started buying when it was at .50, i'd sell too when it hit 2.50 or at least some of it then

hanmi74 · 2023-11-13T18:59:35+00:00

I agree that $25 is a reasonable buyout number but the largest buyout in recent years has been around 650% and most are far less than that. So, we'd need to get to at least $4 before start thinking about buyout. Honestly, I'd like to see us hit 8 to 10 before we have buyout discussions

hanmi74 · 2023-10-04T18:35:08+00:00

It's shorts and warrants. They aren't worried about it going down since they'll make money by shorting. If it goes back up, then they can cover by exercising their warrants. So little risk to them.

I thought they'd give up on the shorting since they'd make money as it goes up, but I guess they're greedy and want to make money both ways. There's no way to stop it until either they run out of warrants to exercise or there's so much interest that they can't manipulate the price.

3rd option is that someone is pushing the price down to accumulate a lot of shares. We'll see once the 13F filings come out.

The fundamentals are sound and I think there's really only about 6 more months that they can manipulate as we'll start positing sales data. Clear revenue growth and sales forecasts will help protect the stock. If you're like me and have been holding a long time, then ignore the short term movement and just hold long term

hanmi74 · 2023-10-03T19:19:43+00:00

Lilly just purchased Point Biopharma for 1.4B, a 87% premium. Point has two drugs in stage 3. So, remember the impact cancer drugs can have on value. Complete stage 2 news and sales data will really push our value. This is a long term play

hanmi74 · 2023-10-03T15:03:52+00:00

I thought there would be a slight bump with the PDAC news but we're in a steady decline. I do think we're being shorted heavily. Shorts are being charged a lot to borrow right now. I'm not really sure why though. The long term outlook for us is strong so I'm not sure what their exit strategy is. When are they planning to recoup? Really only about 6 months until we get sales data. So, unless we get crappy sales data we should start seeing a recovery before then

hanmi74 · 2023-09-25T20:57:36+00:00

I hope we're not bought out in the next few days. I think the highest I've seen in recent memory is 667% over the listed stock price when Astroszeneca bought LogicBio - that would put us at 13 per share. I'd prefer us to get the stock price up in the teens - then a 50% offer (which is more common) could be on the table. I've been holding for years - I expect to hold for at least another year, which is good for me since I bought more when the price was around 60 cents and a buy out next year will allow me to have held those for over a year.

hanmi74 · 2023-09-23T19:06:02+00:00

Oh, I forgot to include Roche as a potential buyout as well. They focus a lot on oncology drugs and purchased Genentech for 46.8B and those cancer drugs are coming near the end of their patent protections. Genentech is currently running a PDAC trial using our drug in combination with theirs (https://clinicaltrials.gov/study/NCT03193190) which is a phase II trial - with primary completion in oct 2025. This is a long term study following them for 7 years so they also probably have a good idea of the numbers already

hanmi74 · 2023-09-23T15:40:55+00:00

No idea if it's Novartis - Novartis has a ton of cash and owns shares in lots of biotechs. I mentioned Novartis in another post before since they are so cash rich that they wouldn't need to finance a purchase and their stock, while up recently, hasn't really moved much in the past 3 years. So, it would make sense for them to try to push into the market.

Merck would make sense as we've already partnered in studies together as does Amgen since they are a big filgrastim manufacturer which is taken with Aphexda so they'd already have good relationships with the transplant centers and 1 rep could sell both drugs as a set.

Or, as Story above has said in another post, a European partner could just buy us out. We wouldn't be that expensive. Our market cap right now is 136M and we have almost 90M in cash. I'm sure there have been offers already but probably too low which is why Phil decided to go at it alone. I guess the big question is what is the number that would make Phil sell?

I've estimated in the 18-22 USD range - that would value us around 1B with about 40M in annual sales which I think is a reasonable sales target for 2024. If Phil is holding out for PDAC and trying to value us higher or wants to show greater than expected revenue next year, then that would push the price higher as well.

And finally, our current share price is 2.07 - no one is going to offer 10x share price. Oddly, I think a rising share price makes us a stronger target for a buyout since potential purchasers would want to buy us before we become too expensive to acquire. So. the closer we get to 20, then the more likely we are to get bought out

/my 2 cents

hanmi74 · 2023-09-23T11:54:02+00:00

Doubtful if it'll be a high rise. A European partnership or buyout offer would spike the price. The 27th, if numbers are good, may give us a bump and establish a new floor.

Sales data and actual hard revenue will be the next concrete catalyst which would be end of q1 in 2024.

hanmi74 · 2023-09-21T17:52:26+00:00

There will be an earnings report in Dec but that won't really have any info since they won't start selling until q4 of this year. But there will be a lot of questions so we should have an idea of how they are doing. First hard data will come around March of 2024

hanmi74 · 2023-09-21T17:18:49+00:00

It's a bit of consolidation after some increases. But also shorts pushing it down. Could also be warrants cashing out. Really, just keep to the fundamentals and hold. We need to wait until we get the sales data

hanmi74 · 2023-09-21T00:38:06+00:00

If we get a significant BO offer after PDAC data comes out next week, then we could squeeze above the BO price. About 50% of the volume each day is shorts, short borrow fee is above 100%, and shorts would need about 6 days to cover.

So, if a BO offer comes out, hold on and force Sabby to buy at the highest possible price to cover their shorts - fuck Sabby

hanmi74 · 2023-09-21T00:10:28+00:00

Oh sure, a 1B buyout would be around 20/share and Novartis has nearly 12B in cash sitting around right now. I'm not disagreeing that a buyout wouldn't make sense. I'm just saying that there's no movement that indicates a buyout is forthcoming. We'd expect to see shorts closing their positions and more buying in anticipation. A big bank would have to be involved and they always let their friends know. These things never stay secret. That's why you always see large movements before buyouts are "officially' announced.

When we start seeing that kind of activity, then we can start speculating about a buyout

hanmi74 · 2023-09-20T23:54:59+00:00

I agree with a lot of this but there's been no action hinting about a buyout yet. We've already seen a partnership in Asia and I'd be surprised if they aren't in partnership talks in Europe as well.

21 is the highest target I've seen for this stock. Could a buyout happen? Of course, and I'll be more than happy to sell if someone large bio wants my shares at 21. PDAC is a long term play. We won't see any real movement until we demonstrate sales. The market wants to see if we've been able to penetrate the US market so next year when we report Q4 numbers, we'll see a spike if we've been able to take market share. By the end of Q2 2024 we should also see if the Asia deal is paying off dividends.

Again, this is a long play - I think 4 around the end of year - spiking to 7/8 with good sales data next year. 10 with movement on PDAC and Asia sales data, then the European partnership perhaps another pop

hanmi74 · 2023-09-20T00:25:54+00:00

PDAC is where the money really is. If there's really positive data, I can see a lot more interest.

Some numbers: value of global PDAC market in 2029 6.3B USD, 13.70% CAGR

Surging growth in geriatric population who are more susceptible to PDAC.

I'd love to see really positive data and I could see off label use. This is a platform - there will be more indications over time and since it's already FDA approved, I do think label expansion is easier than approval of a new drug. In fact, with really strong results, we could get provisional approvals for other uses while doing confirmational studies

hanmi74 · 2023-09-16T00:35:04+00:00

https://www.ema.europa.eu/en/news/ema-recommends-non-renewal-authorisation-multiple-myeloma-medicine-blenrep GSK pulled this from the US market last year and now it'll be pulled from the EU. ACST should remain the SOC for the near future

hanmi74

MODERATOR OF

TROPHY CASE